The SAILOR study, the largest trial in exudative AMD to date (n = 4307), was a Phase IIIb multicenter, 1-year study evaluating a variable-dosing regimen of 3-monthly intravitreal ranibizumab (0.3 ...

Introduction/Background Anti-VEGF Dosing Regiments: Review of the Pertinent Studies Comparing the Anti-VEGF Dosing Strategies Conclusions References While ...